Cefotaxime treatment of gram-negative enteric meningitis in infants and children.
18 infants and children (1 week to 3 months of age) were treated with cefotaxime 200 mg/kg/day for Gram-negative enteric bacillary meningitis. 17 of these patients (94.4%) survived, with a complication rate of 23.5% (4/17 patients). The follow-up cerebrospinal fluid cultures at 24 hours were sterile in all patients. Cefotaxime was safe and effective in treating Gram-negative enteric bacillary meningitis in infants and children and should be considered as a potential drug of choice in Gram-negative neonatal meningitis due to susceptible organisms.
Jacobs
R F
RF
Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock.
D002439:Cefotaxime / Q000009:adverse effects / Q000627:therapeutic use*; D004754:Enterobacter / Q000302:isolation & purification; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D005500:Follow-Up Studies; D006090:Gram-Negative Bacteria / Q000302:isolation & purification*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007711:Klebsiella pneumoniae / Q000302:isolation & purification; D008297:Male; D008581:Meningitis / Q000188:drug therapy* / Q000382:microbiology
D002439:Cefotaxime